Price (delayed)
$5.01
Market cap
$724.53M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.54
Enterprise value
$773.27M
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The
There are no recent dividends present for AUPH.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.